CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04389840
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:00.530538+00:00
Published At: 2022-08-30T00:00:00+00:00
Record Updated At: 2022-08-30
Results Posted At: 2022-08-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Coronavirus Disease 2019 (COVID-19)", "Acute Lung Injury", "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-30"
protocolSection.identificationModule.nctId: "NCT04389840"
protocolSection.identificationModule.officialTitle: "A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-08-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.